Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

MINERVA NEUROSCIENCES (NERV)

39 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. [verwijderd] 2 juni 2017 18:39
    Attractive Stock of Minerva Neurosciences, Inc.’s (NERV) stock price is Worth at $10.00 while ends Thursday with move of 21.21%
    June 2, 2017 Robert Ebelling 0 Comment Inc, Minerva Neurosciences, NERV
    Minerva Neurosciences, Inc. (NERV)’s Stock Price Trading Update:
    Minerva Neurosciences, Inc. (NERV), a part of Healthcare sector and belongs to Biotechnology industry; ended its day with gain 21.21% and finalized at the price of $10.00. During its last trading session, Stock traded with the total exchanged volume of 2.88 million shares. The average volume stands around 0.16 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 17.47. Relative volume is ratio between current volume and 3-month average value, intraday adjusted.
    NERV Stock Price Comparison to Moving Averages:
    USA based company, Minerva Neurosciences, Inc. (NERV)’s latest closing price was -7.31% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 32.57% and 33.02% compared with the 20 Day Moving Average.
    Earnings per share Details about NERV:
    EPS growth in next year is estimated to reach -0.70% while EPS growth estimate for this year is set at 14.80%.
    Performance Review:
    To review the NERV previous performance, look at its past history, which highlighted below:
    During last 5 trades the stock sticks almost 36.05%
  2. [verwijderd] 2 juni 2017 18:42
    Minerva Neurosciences Inc (NERV) Receives Outperform Rating from JMP Securities
    June 2nd, 2017 - By Doug Wharley - 0 comments
    JMP Securities reissued their outperform rating on shares of Minerva Neurosciences Inc (NASDAQ:NERV) in a research note issued to investors on Thursday. The brokerage currently has a $20.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $17.00.
    A number of other research analysts also recently weighed in on the company. Zacks Investment Research upgraded Minerva Neurosciences from a sell rating to a hold rating in a report on Wednesday, April 5th. ValuEngine upgraded Minerva Neurosciences from a sell rating to a hold rating in a report on Tuesday, May 23rd. Finally, Jefferies Group LLC started coverage on Minerva Neurosciences in a report on Monday, March 6th. They set a buy rating and a $17.00 price target on the stock.
  3. [verwijderd] 2 juni 2017 18:52
    Zacks: Minerva Neurosciences Inc (NERV) Receives Consensus Rating of “Strong Buy” from Analysts
    Posted by Lauren Steadman on Jun 1st, 2017 // No Comments
    Shares of Minerva Neurosciences Inc (NASDAQ:NERV) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
    Analysts have set a 12-month consensus price target of $17.00 for the company and are predicting that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also given Minerva Neurosciences an industry rank of 159 out of 265 based on the ratings given to related companies.
  4. [verwijderd] 21 juni 2017 22:07
    Zoals PM eergisteren feilloos aangaf is goud aan het stijgen vandaar de koersstijging vandaag bij NUGT. In theorieboekjes wordt altijd uitgelegd dat een rentestijging de goudprijs onder druk zou zetten. PM staat uiteraard boven deze materie en voorspelt dat net als bij de andere renteverhogingen door de FED dat goud fors in waarde zal STIJGEN. Ja STIJGEN. Daarom NUGT. Deze stijging zal met horten en stoten gaan maar PM verwacht voor augustus een goudprijs fors boven de 1300 dollar.
    Om die reden zetten Profitmaker de helft van de positie in NERV (meer dan 30% winst in paar maanden) om naar NUGT waar PM dus veel van verwacht. Nerve zal voor d zomer naar 10 plus gaan verwacht PM. Nugt minimaal naar de range 35-40 dollar plus.
  5. [verwijderd] 27 juni 2017 21:31
    quote:

    Profitmaker schreef op 27 juni 2017 20:59:

    Een uitgelezen kans om vandaag Nerv te kopen! Aandeel wordt bij laag volume fors lager gezet.
    PM heeft dat vandaag ook gedaan op 8,80!
    Logisch, meer verkopers dan koper of dat vertrouwen geeft is de vraag. #AVEO en #MBRX doen het beter de laatste dagen.
39 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 877,43 +0,30%
EUR/USD 1,0693 -0,09%
FTSE 100 8.064,60 +0,25%
Germany40^ 18.123,60 -0,08%
Gold spot 2.318,49 -0,15%
NY-Nasdaq Composite 15.696,64 +1,59%

Stijgers

VIVORY...
+17,36%
ASMI
+12,11%
NX FIL...
+4,81%
BESI
+3,93%
RANDST...
+3,80%

Dalers

ALLFUN...
-10,04%
ING
-6,01%
WDP
-2,51%
Avantium
-2,37%
Flow T...
-1,99%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links